Executive interview – InflaRx

Published on 10 December 2018

CEO and founder, Niels Riedemann, discusses InflaRx’s core technology including its lead product, IFX-1. He also highlights the advantages of the company’s acute and chronic inflammation products versus the current standard of care and the competition. Finally, he provides an update on InflaRx’s expected near-term news flow.

Share this with friends and colleagues